Event
Alzheimer’s disease and Parkinson’s disease Conference (AD/PD)
Date: 17-21 March 2026
Location: Copenhagen, Denmark
Aurelie Dos Santos,
Business Development Associate BD & Sales Benelux
Silvia Cainarca, Scientific Officer
Donatella Bardelli, Principal Scientist, Advanced Cellular Assays
Axxam at the Alzheimer’s Disease and Parkinson’s Disease Conference (AD/PD)
Axxam will participate in the Alzheimer’s disease and Parkinson’s disease Conference (AD/PD), one of the leading international meetings dedicated to neurodegenerative disease research and therapeutic development.
During the conference, our team will present new scientific insights and connect with researchers and industry partners working on innovative strategies to better understand and treat Alzheimer’s disease, Parkinson’s disease, and related neurodegenerative disorders.
The conference provides an important opportunity to discuss how advanced in vitro disease models and screening technologies can accelerate the discovery of new therapies targeting complex neurological disorders.
Poster Presentation
Our Principal Scientist Donatella will present the poster:
“Aiming at organelles as targets for treatment in neurodegenerative diseases.”
The work focuses on developing screening assays and disease-relevant neuronal models to investigate how dysfunction in critical organelles, such as lysosomes and mitochondria, contributes to neurodegenerative diseases.
Using advanced experimental approaches including high-content imaging, electrophysiology, and cellular models, the study explores how organelle dysfunction and protein aggregation can be leveraged as therapeutic targets for drug discovery.
Talk at the FCDI Booth
Our Scientific Officer Silvia will also give a talk at the FCDI booth (#62) during the conference.
iPSC Models for Neurodisorders: De-risking and Accelerating Drug Discovery
📅 Wednesday, March 18
⏰ 2:00 PM
📍 FCDI Booth #62
Session: “Science & Sweets”
During the presentation, Silvia will discuss how induced pluripotent stem cell (iPSC)-derived models can improve the translational relevance of early drug discovery programs in neurodegenerative diseases.
By using human iPSC-derived neuronal models, researchers can better reproduce disease-relevant phenotypes and study complex biological mechanisms that are difficult to capture using traditional cellular systems.
The Role of iPSC Models in Neurodegenerative Disease Research
Neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease involve complex cellular mechanisms including:
- protein aggregation
- mitochondrial dysfunction
- lysosomal impairment
- neuronal degeneration
Induced pluripotent stem cells (iPSCs) have become powerful tools to study these processes because they enable the generation of human disease-relevant neuronal models.
At Axxam, iPSC-derived models are integrated with advanced technologies such as:
- high-content imaging
- electrophysiology
- multielectrode array recordings
- organelle-focused functional assays
These platforms allow researchers to investigate disease mechanisms and identify new therapeutic targets and compounds with higher translational relevance.
Meet Axxam at AD/PD
If you are attending the AD/PD Conference, we would be happy to connect.
Our team will be available to discuss:
- iPSC-based disease models for neurodegeneration
- assay development for complex neuronal systems
- screening strategies for neurodegenerative targets
- collaboration opportunities in early-stage drug discovery
Interested in neurodegeneration research?
💡Join our upcoming webinar
“α-Synuclein and Organelles: Key Players in the Neurodegeneration Puzzle”
Discover how α-synuclein and organelle dysfunction drive disease mechanisms in our webinar.
16 April 2026, 16:00 CEST / 10:00 EDT / 07:00 PDT